Welcome to our dedicated page for Cytokinetics SEC filings (Ticker: CYTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cytokinetics, Incorporated (CYTK) SEC filings page on Stock Titan brings together the company’s public reports filed with the U.S. Securities and Exchange Commission. Cytokinetics is a Nasdaq-listed specialty cardiovascular biopharmaceutical company focused on muscle biology and diseases of cardiac muscle dysfunction, and its filings provide detailed information about its operations, capital structure and regulatory progress.
Recent Form 8-K current reports from Cytokinetics include disclosures about regulatory milestones for MYQORZO (aficamten), such as a positive opinion from the Committee for Medicinal Products for Human Use of the European Medicines Agency for symptomatic obstructive hypertrophic cardiomyopathy. Other 8-K filings describe financial results, the issuance of convertible senior notes due 2031, planned draws under a development funding loan agreement and executive appointments and compensation arrangements.
Investors reviewing CYTK filings can also track information about the company’s listing on The Nasdaq Global Select Market, its equity incentive plans, inducement grants under Nasdaq Listing Rule 5635(c)(4) and its use of proceeds from capital raises to support the potential commercial launch of aficamten and the advancement of its development pipeline. Additional SEC documents, such as annual and quarterly reports when available, typically include discussions of clinical programs in hypertrophic cardiomyopathy and heart failure, risk factors and financial statements.
On Stock Titan, these SEC filings are updated as new documents are released on EDGAR, and AI-powered tools can help summarize key points from lengthy reports so readers can more quickly understand the context and implications of Cytokinetics’ regulatory and financial disclosures.
Cytokinetics (CYTK) reported an insider transaction by a director. On 10/15/2025, the director acquired 199 shares of common stock at $62.8 per share. Following the transaction, the director beneficially owns 20,692 shares, held directly.
The filing notes this was director equity in lieu of a cash retainer, indicating compensation received in stock rather than cash.
Insider exercise and sale by Cytokinetics EVP R&D. On
CYTOKINETICS, Inc. director Dr. Edward M. Kaye reported a sale of 6,757 shares of common stock on
Insider sale notice for CytoKinetics (CYTK). An individual proposes to sell 6,757 common shares with an aggregate market value of
The filing also discloses recent automated sales under a 10b5-1 plan: 6,695 shares sold on
Form 144 notice for CYTK reports a proposed sale of 15,000 common shares through Morgan Stanley Smith Barney on NASDAQ, with an aggregate market value of $824,400 and an approximate sale date of 10/01/2025. The shares were acquired as restricted stock units on 03/06/2021. The filing lists five prior 10b5-1 sales by the same person during Jul–Sep 2025 totalling 25,000 shares and gross proceeds shown for each trade. The filer certifies no undisclosed material adverse information and that the sale complies with Rule 144 and any applicable 10b5-1 plan.
Robert I. Blum, President & CEO and Director of Cytokinetics, reported a sale of common stock on 10/01/2025. The Form 4 shows 5,000 shares were disposed of at a price of $55.05. After the reported sale, the filing lists 368,108 shares held directly and 2,083 shares held indirectly by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held indirectly by The Brittany Blum 2003 Irrevocable Trust. The form was signed by an attorney-in-fact on behalf of Mr. Blum.
Insider sale disclosed: Dr. Edward M. Kaye, a director of Cytokinetics, Inc. (CYTK), reported a sale of 6,695 shares of the company's common stock on 09/30/2025 at a price of $55.08 per share. After this reported transaction, Dr. Kaye beneficially owned 16,535 shares, held directly. The Form 4 was signed by an attorney-in-fact, John Faurescu. The filing presents a single non-derivative sale and no derivative transactions were reported.
CYTOKINETICS, INC. (CYTK) Form 144 notice reports a proposed sale of 6,695 common shares valued at $360,793.55, to be sold through Morgan Stanley Smith Barney on 09/30/2025 on NASDAQ. The shares were acquired as restricted stock units on 10/01/2021 from the issuer and payment was recorded as N/A. The filing also discloses recent 10b5-1 sales by the reported person: 6,756 shares sold on 09/02/2025 for $337,800.00. The filer affirms no undisclosed material adverse information and references Rule 10b5-1 trading plan requirements.
Malik Fady Ibraham, EVP Research & Development at Cytokinetics (CYTK), reported transactions on 09/23/2025. He exercised 2,000 stock options at an exercise price of $10.60 (non-qualified options exercisable since 03/28/2017, expiring 02/28/2027) and acquired 2,000 shares. He simultaneously sold 2,000 shares at $49.28, leaving him with 140,610 shares beneficially owned. The filing was signed by an attorney-in-fact and the box indicating a 10b5-1 plan was checked.
Cytokinetics, Inc. filed an 8-K reporting an Indenture dated September 19, 2025 with U.S. Bank Trust Company, N.A. as trustee that governs the company's 1.75% Convertible Senior Notes due 2031. The filing describes events that would constitute defaults under the Indenture, including failures to pay principal or interest, failures to send required notices, breaches of certain covenants (including on mergers or asset transfers), failures to effect conversions within five business days, uncured defaults under other obligations, specified defaults by significant subsidiaries on indebtedness of at least $50,000,000, and bankruptcy or insolvency events. The filing includes the form of the Note (Exhibit A), press releases dated September 16, 2025, and an interactive cover page XBRL file. The document is signed by Sung H. Lee, Executive VP and CFO.